Cencora, Inc. announced on July 15, 2025, the execution of a distribution services agreement with Citius Oncology, Inc. for LYMPHIR (denileukin diftitox-cxdl). LYMPHIR is an FDA-approved immunotherapy indicated for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This agreement expands Citius Oncology's commercial distribution network and reinforces launch readiness for LYMPHIR. Cencora will serve as a wholesale distributor, providing specialty distribution services to facilitate product availability across its network.
The partnership strengthens Cencora's role as a leader in specialty pharmaceutical distribution and services, enhancing its ability to deliver critical therapies to treatment centers nationwide. This collaboration is a foundational step in supporting the market introduction and long-term scalability of LYMPHIR.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.